HONG KONG – With an NDA for tislelizumab currently under review at the National Medical Products Agency (NMPA) for relapsed or refractory classical Hodgkin lymphoma, China biotech Beigene Ltd. started enrolling patients into two global phase III trials testing the PD-1-inhibiting antibody in gastric cancer and esophageal squamous cell carcinoma (ESCC).